GCMS BASED METABOLIC PROFILING OF ESSENTIAL OIL OF CITRUS MACROPTERA MONTRUZ. LEAVES AND PEEL, ASSESSMENT OF IN VITROANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITY

Objective: The present investigation was designed for Gas Chromatography Mass Spectrometry (GCMS) based metabolite profiling of Citrus macroptera Montruz. Leaves and peel oils followed by assessment of in vitro antioxidant and anti-inflammatory activity.Methods: Essential oil was extracted from leaves and peels of Citrus macroptera Montruz. The oil samples were subjected to GCMS analysis using Shimadzu GCMS-QP2010 equiped with an AOC-2oi auto-injector and AOC-2os autosampler units. In vitro antioxidant activities were evaluated using DPPH radical scavenging, reducing power and nitric oxide reducing method. In vitro anti-inflammatory activity was evaluated using protease inhibitory assay, heat induced haemolysis and albumin denaturation assay.Results: Both the peels and leaves of Citrus macroptera Montruz. Yielded good amount of essential oil. 57 compounds each were identified from leaves as well as peel of C. macroptera. 10 common compounds have been detected in both the oil samples. Peels oil showed IC50 at 118.07 µg/ml and that of leaves showed IC50 at 252.93 µg/ml in DPPH (1, 1-diphenyl-2-picrylhydrazyl) assay. In reducing assay, peel and leaves oil showed IC50 at 122.5 µg/ml and 208.24 µg/ml. In albumin denaturation, the peels showed IC50 at 73.91 µg/ml and that of leaves showed IC50 at 87.48 µg/ml.Conclusion: The oil yield denotes peel as better source of volatile oil than leaves. Essential oil of peel showed more anti-oxidant and anti-inflammatory activity than that of leaves essential oil

Colorectal Cancer Immunotherapy: State of the Art and Future Directions

Cancer immunotherapy has become an indispensable mode of treatment for a multitude of solid tumor cancers. Colorectal cancer (CRC) has been one of the many cancer types to benefit from immunotherapy, especially in advanced disease where standard treatment fails to prevent recurrence or results in poor survival. The efficacy of immunotherapy in CRC has not been without challenge, as early clinical trials observed dismal responses in unselected CRC patients treated with checkpoint inhibitors. Many studies and clinical trials have since refined immunotherapies available for CRC, solidifying immunotherapy as a powerful asset for CRC treatment. This review article examines CRC immunotherapies, from their foundation, through emerging avenues for improvement, to future directions